NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 6 மணி நேரத்திற்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Yatharth Reports Q2FY27 Revenue Up 52% YoY; Outlines ₹3,150 Cr Advent Partnership to Reach 8,000 Beds
Yatharth Hospital submitted its Q2FY27 earnings call transcript highlighting a 52% YoY revenue surge and 50% YoY EBITDA growth. Management highlighted a major strategic primary investment of ₹3,150 crore from Advent International via preferential shares and warrants (equivalent to ~32% of its current market cap of ₹9,857 crore), aimed at expanding bed capacity from ~2,800 to 7,000–8,000 beds over the next 3 to 5 years. Blended ARPOB rose 11% YoY to approximately ₹36,000 with hospital occupancy at 72%. Newer turnaround assets like Faridabad Sector-20 and Model Town generated quarterly revenues of ₹40 crore and ₹26 crore respectively, with Model Town expected to achieve breakeven in H2FY27.
உச்சம் நம்பிக்கை
என்ன மாறியதுSubmission of the Q2FY27 earnings call transcript clarifying operational metrics and operational integration plans for the Advent International partnership.
ஏன் இது முக்கியம்The massive ₹3,150 crore capital infusion significantly de-risks the company's aggressive inorganic expansion target to nearly triple bed capacity to 7,000–8,000 beds.
Advent Fundraise: ₹3,150 கோடிFundraise vs MCap: ~32.0%Q2 YoY Revenue Growth: 52%Blended ARPOB: ₹36,000Capacity Target: 7,000 to 8,000 beds
📅 குறுகிய காலம்Market sentiment should stay supported by strong 50%+ top-line growth and turning turnaround hospitals EBITDA-positive.
📈 நீண்ட காலம்If executed successfully, the Advent partnership provides ample capital firepower to scale into a multi-region healthcare chain of up to 8,000 beds.
⚠ அபாய எச்சரிக்கைகள்
Pending regulatory approvals for the ₹3,150 crore preferential issue.
Integration and valuation risks associated with aggressive inorganic acquisitions.
👀 கவனிக்க வேண்டியவை
Track the receipt of regulatory approvals and closing timeline for the ₹3,150 crore Advent transaction, along with operationalization dates for the upcoming 250-bed Gurugram hospital in FY28.
Yatharth Hospital Gets CCI Nod for ~₹3,150 Cr Preferential Issue of 24.87% Stake
Yatharth Hospital has received approval from the Competition Commission of India (CCI) on November 10, 2026, for its proposed preferential issue to Cyprus-based Rasmalai Limited. The company plans to issue securities for an aggregate cash consideration of ~₹31,500 million (~₹3,150 crore), representing a 24.87% minority stake on a fully diluted post-issue basis. Relative to Yatharth's current market cap of ₹9,693 crore, this capital raise represents ~32.5% of its equity value. The transaction remains subject to other regulatory and statutory requirements before closing.
உச்சம் நம்பிக்கை
என்ன மாறியதுCompetition Commission of India (CCI) has formally cleared the ₹3,150 crore preferential allotment to Rasmalai Limited.
ஏன் இது முக்கியம்A fundraise of this magnitude (~1.87x current net worth of ₹1,682 crore) provides massive capital for Yatharth's stated goal of scaling to ~3,000 beds, though it involves ~24.87% equity dilution.
Issue consideration: ~ INR 31,500 millionPost-issue stake: 24.87%Fundraise vs Market Cap: ~32.5%Fundraise vs Net Worth: ~187%CCI Approval Date: நவம்பர் 10, 2026
📅 குறுகிய காலம்Positive sentiment from clearing a major antitrust regulatory hurdle, paving the way for remaining closing conditions.
📈 நீண்ட காலம்Transformational balance sheet expansion with ~₹3,150 crore in fresh cash, enabling aggressive greenfield and brownfield M&A across North India, offset by equity dilution.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution of 24.87% on a fully diluted basis
Pending other applicable statutory and regulatory clearances
Capital allocation and execution risk across large-scale hospital expansions
👀 கவனிக்க வேண்டியவை
Track subsequent regulatory clearances, shareholder approval timelines, and the ultimate deployment schedule of the ₹3,150 crore proceeds toward hospital expansions or debt reduction.
Yatharth Reports Q2FY27 Revenue Up 52% to ₹431.4 Cr; Advent to Invest ₹3,150 Cr for 24.9% Stake
Yatharth Hospital delivered strong Q2FY27 results with revenue surging 52% YoY to ₹431.4 crore (Rs 4,314 mn) and PAT climbing to ₹48.5 crore (Rs 485 mn). EBITDA stood at ₹102.0 crore with margins of 23.6%, while ARPOB grew 11% YoY to ₹35,948 at 72% occupancy. Additionally, global PE firm Advent is set to infuse ₹3,150 crore in primary capital for a 24.9% stake (awaiting regulatory approvals), which represents ~35.6% of the company's current ₹8,837 crore market cap. Bed capacity reached 2,800+ beds, supported by ongoing additions in Gurugram, Model Town, and Faridabad.
உச்சம் நம்பிக்கை
என்ன மாறியதுYatharth released its Q2FY27 investor presentation highlighting 52% YoY top-line growth and a transformative ₹3,150 crore primary equity raise agreement with Advent.
ஏன் இது முக்கியம்The massive primary fundraise will significantly deleverage and capitalize the balance sheet for large-scale bed expansions across North India while validating the operating platform.
📅 குறுகிய காலம்Market sentiment should be strongly supported by both the 50%+ operating growth and the institutional backing from Advent.
📈 நீண்ட காலம்Capital from Advent and scaling bed capacity to 2,800+ positions Yatharth as a dominant tertiary care hospital network in Delhi-NCR and North India.
⚠ அபாய எச்சரிக்கைகள்
Regulatory approval required for the Rs 3,150 crore primary capital infusion
Dilution of promoter holding from 55.8% to ~42%
Gestation drag from ramp-up of newer hospitals impacting near-term blended margins
👀 கவனிக்க வேண்டியவை
Track receipt of regulatory approvals for the ₹3,150 crore Advent capital infusion and monitor margin ramp-up at new hospital units (Model Town, Faridabad, and Gurugram).
Yatharth Hospitals Q2FY27 Revenue Up 52% YoY to ₹431.4 Cr; PAT Rises 17% to ₹48.5 Cr
Yatharth Hospital reported strong financial performance for Q2FY27 with revenue growing 52% YoY to ₹431.4 crore (₹4,314 mn) and EBITDA increasing 50% YoY to ₹102.0 crore. PAT grew 17% YoY to ₹48.5 crore, constrained by higher depreciation from aggressive capacity additions. Group ARPOB expanded 11% YoY to ₹35,948, with newly acquired hospitals contributing 28% of quarterly revenue. The company also highlighted a definitive agreement for a ₹3,150 crore primary capital infusion from Advent International (representing ~35.6% of current market cap) to expand bed capacity to 7,000-8,000 beds.
உச்சம் நம்பிக்கை
என்ன மாறியதுYatharth announced its Q2FY27 financial results showing 52% YoY revenue growth and reinforced progress on its definitive ₹3,150 crore primary fundraise agreement with Advent International.
ஏன் இது முக்கியம்Acquisitions are scaling rapidly (now contributing 28% of revenue vs 11% last year), and the massive ₹3,150 cr proposed fund infusion provides clear visibility to scale towards 7,000-8,000 beds over the long term.
📅 குறுகிய காலம்Earnings show continued operational ramp-up across newly integrated assets, which should support sentiment. Key near-term event is the earnings call on November 4, 2026, at 11:00 am IST.
📈 நீண்ட காலம்The company is transitioning from a regional NCR player into a significantly larger multi-hospital chain, with substantial growth runway supported by Advent's growth capital to scale bed capacity towards 7,000-8,000 beds.
⚠ அபாய எச்சரிக்கைகள்
Regulatory approval risks pending for the Advent primary capital deal
Equity dilution of ~24.9% upon full conversion of shares/warrants
Short-term margin drag and higher depreciation from integrating newly acquired units
👀 கவனிக்க வேண்டியவை
Track the regulatory approvals and shareholder voting for the ₹3,150 crore Advent transaction, along with margin turnaround and EBITDA breakeven progress at the New Delhi hospital in H2FY27.
Yatharth Hospital Q2 Standalone Net Profit Up 79.5% YoY to ₹37.06 Cr; Revenue at ₹194.9 Cr
Yatharth Hospital reported strong Q2 FY27 standalone numbers with revenue from operations growing 40.8% YoY to ₹194.91 Cr (INR 1,949.06 Mn) compared to ₹138.37 Cr in Q2 FY26. Standalone Net Profit jumped 79.5% YoY to ₹37.06 Cr against ₹20.64 Cr in the corresponding quarter last year. Notes to results highlighted that Advent International affiliate Rasmalai Limited received shareholder approval on October 15, 2026, to acquire a 24.9% equity stake (pending regulatory approvals). Additionally, the company received total Income Tax demand orders of ~₹68.0 Cr (including interest across parent and subsidiaries) which it has appealed before CIT (Appeals) without creating provisions.
உச்சம் நம்பிக்கை
என்ன மாறியதுApproved Q2 and H1 FY27 financial results showing robust topline and bottomline expansion, while updating on the 24.9% Advent investment and income tax disputes.
ஏன் இது முக்கியம்Demonstrates sustained operational momentum across hospitals with nearly 41% topline growth, while the pending partnership with Advent provides strategic validation.
Standalone Revenue (Q2): INR 1,949.06 millionStandalone Net Profit (Q2): INR 370.61 millionDiluted EPS (Q2): INR 3.85Advent Proposed Stake: 24.9%Income Tax Demand (Holding Co): INR 296.62 million plus interest of INR 114.20 million
📅 குறுகிய காலம்Market reaction is likely to be positive driven by ~80% YoY growth in standalone Q2 PAT, though investors will eye consolidated metrics and tax contingency updates.
📈 நீண்ட காலம்Expansion in high-value specialties and prospective backing from PE major Advent International (24.9% stake) support the company's planned capacity scale-up towards 3,000 beds.
⚠ அபாய எச்சரிக்கைகள்
Unprovided Income Tax assessment demands totaling over ₹68 Cr across holding company and subsidiaries pending in appeal
Pending regulatory approvals for the 24.9% stake sale to Advent International affiliate
👀 கவனிக்க வேண்டியவை
Track the receipt of regulatory approvals for the 24.9% Advent International stake transaction and monitor progress on the CIT (Appeals) proceedings regarding the IT tax demands.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Yatharth Hospital Shareholders Approve Preferential Issue and Capital Hike at EGM
Yatharth Hospital has secured shareholder approval for all five resolutions tabled at its Extraordinary General Meeting held on October 15, 2026. The key approvals include an increase in authorized share capital, issuance of securities (equity shares and warrants) via preferential issue, and granting special rights to investors and promoters. Notably, resolution 2 for the preferential issue passed with 99.26% overall votes in favour, though institutional resistance was elevated on governance terms. Resolution 5 regarding an Upside Share Arrangement witnessed 38.45% votes against, passing with 61.55% approval as promoters were ineligible to vote.
உச்சம் நம்பிக்கை
என்ன மாறியதுShareholders officially approved the preferential allotment of shares/warrants and related investor rights agreements at the EGM.
ஏன் இது முக்கியம்The approval clears regulatory requirements for onboarding a strategic financial investor and raising fresh equity capital to fund its bed capacity target expansion toward ~3,000 beds.
📅 குறுகிய காலம்Clearance of voting removes procedural uncertainty around the preferential fundraise, with market focus now shifting to allotment notices and pricing.
📈 நீண்ட காலம்Securing equity capital supports Yatharth's stated strategy to expand bed count from 1,185 toward 3,000, though substantial dissent by institutional investors on special rights warrants governance monitoring.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution from preferential shares and warrants
High institutional investor dissent (over 40%) on special rights and upside sharing arrangements
👀 கவனிக்க வேண்டியவை
Track subsequent exchange disclosures detailing the exact issue price, total capital raised, dilution quantum, and specific deployment towards planned hospital expansions (e.g., Faridabad, Model Town, Agra).
Yatharth Concludes EGM on Preferential Issue to Advent International Affiliate
Yatharth Hospital concluded its Extra-Ordinary General Meeting on October 15, 2026, to approve a strategic preferential issue of equity shares and warrants to Rasmalai Limited, an affiliate of Advent International. The EGM saw attendance from 74 members (4 promoter group, 70 public) out of 101,829 total shareholders as of October 8, 2026. Key resolutions put to vote included increasing authorised share capital, preferential issuance, amendment of Articles of Association, special investor rights, and an upside share arrangement. Scrutinizer voting results under Regulation 44(3) are awaited to confirm formal shareholder approval.
உச்சம் நம்பிக்கை
என்ன மாறியதுShareholders have voted on a strategic preferential investment by Advent International's affiliate, with final voting scrutiny underway.
ஏன் இது முக்கியம்Backing from a major global PE firm like Advent International provides growth capital and balance sheet support to fund network expansion and capacity targets towards 3,000 beds.
Members present at EGM: 74Total members on cut-off date: 101829Cut-off date: அக்டோபர் 08, 2026Total resolutions put to vote: 5
📅 குறுகிய காலம்Scrutinizer voting outcome expected within two working days; formal approval will clear the path for allotment of equity shares and warrants.
📈 நீண்ட காலம்Strategic backing by Advent International brings governance support, operational expertise, and capital to accelerate hospital network expansions in North India.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution from preferential shares and warrants
Special rights granted to incoming investor could alter governance dynamics
👀 கவனிக்க வேண்டியவை
Track the upcoming disclosure of final voting results under Regulation 44(3) and regulatory filings detailing the exact capital raised, dilution percentage, and deployment plans.
Yatharth Hospital has issued a corrigendum to its October 15, 2026 EGM notice following clarifications requested by the NSE regarding its proposed preferential issue. The company is offering 1,30,26,516 equity shares at ₹985.17 per share to raise ₹1,283.33 Cr and up to 1,89,47,664 warrants at ₹985.17 (raising ~₹1,866.67 Cr on exercise). Out of the total proceeds, ₹2,362.50 Cr is earmarked for hospital network expansion and infrastructure development over a 3-year timeline, with the remaining allocated for general corporate purposes.
உச்சம் நம்பிக்கை
என்ன மாறியதுClarifications added to the EGM notice on warrant tenure, valuation mechanism, and detailed 3-year deployment timelines for hospital network expansion.
ஏன் இது முக்கியம்The fundraise (~₹3,150 Cr total upon full conversion) is massive relative to Yatharth's current net worth (₹1,619 Cr) and market cap (~₹9,926 Cr), providing significant capital to accelerate hospital acquisitions and capacity growth.
Equity shares issue size: ₹12,83,33,32,767.72Issue price per share/warrant: ₹985.17Subscription warrants offered: 1,89,47,664EGM Date: அக்டோபர் 15, 2026Fundraise vs Market Cap: ~31.7%
📅 குறுகிய காலம்Shareholder approval at the EGM on October 15, 2026, and receipt of final in-principle exchange approvals will be the immediate milestones.
📈 நீண்ட காலம்If successfully deployed over the stated 3-year horizon, the ~₹2,362 Cr network expansion budget can significantly scale the hospital bed capacity towards its 3,000-bed target.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution of ~3.2 crore shares upon full warrant exercise
Execution risk associated with aggressive hospital acquisitions and integration
👀 கவனிக்க வேண்டியவை
Track the outcome of shareholder voting at the Extraordinary General Meeting on October 15, 2026, and subsequent receipt of final stock exchange in-principle approvals for the preferential allotment.
Yatharth Hospital Calls EGM to Raise Authorised Capital to ₹150 Cr for Preferential Issue
Yatharth Hospital has issued a notice convening an Extra-Ordinary General Meeting (EGM) on October 15, 2026. The company is seeking shareholder approval to increase its authorised share capital from ₹115 crore to ₹150 crore via the creation of 3.50 crore new equity shares. The capital expansion is intended to facilitate the issuance and allotment of subscription shares and warrants to an investor via a preferential issue on a private placement basis. In addition, the agreement establishes reserved matter thresholds including annual M&A up to ₹400 crore and capex up to ₹300 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe board has convened an EGM to amend the Memorandum of Association and approve a preferential issue of equity shares and warrants.
ஏன் இது முக்கியம்Enables an equity infusion to fund hospital network expansions and strategic acquisitions while setting formal governance and capital expenditure limits under the investment agreement.
Current Authorised Capital: INR 115,00,00,000Proposed Authorised Capital: INR 150,00,00,000New Shares Created: 3,50,00,000 equity sharesM&A Reserved Matter Threshold: INR 400,00,00,000 per FYCapex Reserved Matter Threshold: INR 300,00,00,000 per FY
📅 குறுகிய காலம்E-voting runs from October 12 to October 14, 2026, ahead of the October 15 EGM; investor attention will focus on equity dilution and issue pricing details.
📈 நீண்ட காலம்Provides long-term growth capital to accelerate bed capacity additions toward the 3,000-bed target across North India, backed by institutional oversight.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution from preferential shares and warrant conversion
Regulatory approval required from Competition Commission of India (CCI)
👀 கவனிக்க வேண்டியவை
Track voting results of the EGM on October 15, 2026, and watch for subsequent filings disclosing the final issue price, total dilution, and exact identity of the incoming investor.
Yatharth Approves ₹3,150 Cr Preferential Issue to Rasmalai Ltd for 24.87% Stake
Yatharth Hospital has approved a preferential issue of equity shares and warrants to Cyprus-based Rasmalai Limited, raising up to ₹3,150 Cr at ₹985.17 per share. The issue represents 24.87% of the post-issue share capital on a fully diluted basis, comprising 1.30 crore equity shares (₹1,283.33 Cr) and 1.89 crore warrants (₹1,866.67 Cr). This massive capital infusion compares to the company's current market cap of ₹9,792 Cr (~32%) and TTM revenue of ₹1,200 Cr (~2.6x). The deal also includes an upside-sharing agreement rewarding promoter Dr. Ajay Tyagi if the investor achieves >3x return.
உச்சம் நம்பிக்கை
என்ன மாறியதுBoard approved raising ₹3,150 Cr from Rasmalai Limited via shares and warrants, increasing authorised capital to ₹150 Cr and amending MoA/AoA.
ஏன் இது முக்கியம்The fundraise injects capital equivalent to nearly double the company's net worth (₹1,619 Cr), providing massive liquidity to accelerate its 3,000-bed capacity expansion target.
Total fundraise: ₹3,150.00 கோடிIssue price per share/warrant: ₹985.17Diluted stake to investor: 24.87%Fundraise vs Market Cap: ~32.2%Fundraise vs TTM Revenue: ~262.5%
📅 குறுகிய காலம்Stock likely to react to the massive liquidity infusion priced close to current market levels (₹985.17 vs CMP ₹1,044.50), pending shareholder vote at the October 15, 2026 EGM.
📈 நீண்ட காலம்Transformational balance sheet expansion enabling aggressive M&A and greenfield hospital additions across North India, though accompanied by ~25% equity dilution.
⚠ அபாய எச்சரிக்கைகள்
Significant equity dilution of 24.87% on a fully diluted basis
Promoter incentive arrangement tied to investor exit returns requires scrutiny by public shareholders
Subject to shareholder and regulatory/governmental approvals
👀 கவனிக்க வேண்டியவை
Track shareholder approval at the EGM on October 15, 2026, and subsequent deployment plans for the ₹3,150 Cr proceeds toward hospital network expansion.
Advent International to Invest Rs 3,150 Cr for 24.9% Stake in Yatharth Hospitals
Global private equity firm Advent International has entered into a definitive agreement to invest Rs 3,150 crore of primary capital in Yatharth Hospitals for a 24.9% minority stake. The primary capital infusion is highly significant, representing approximately 32% of Yatharth's current market capitalization of Rs 9,792 crore and over 2.6x its TTM revenue of Rs 1,200 crore. The promoter Tyagi family will continue to remain the largest shareholder. The transaction remains subject to customary closing conditions and will support the company's expansion from ~2,800 operational beds across nine hospitals to its announced ~3,250 bed target.
உச்சம் நம்பிக்கை
என்ன மாறியதுAdvent International agreed to inject Rs 3,150 crore of primary equity into Yatharth Hospitals for a 24.9% stake.
ஏன் இது முக்கியம்The massive capital infusion substantially strengthens Yatharth's balance sheet, creating an extensive war chest for aggressive greenfield/brownfield hospital expansions and M&A in North India without incurring debt.
Investment Amount: Rs 3,150 croreStake Acquired: 24.9%Fundraise vs Market Cap: ~32.2%Current Bed Capacity: ~2,800 bedsAnnounced Bed Capacity: ~3,250 beds
📅 குறுகிய காலம்Likely to trigger positive market sentiment due to strong institutional backing from a premier global healthcare investor and substantial capital expansion runway.
📈 நீண்ட காலம்Transformational for Yatharth's scale, accelerating bed capacity expansion, technological upgrades (robotics/oncology), and strategic acquisitions across North India.
⚠ அபாய எச்சரிக்கைகள்
Closing conditions and regulatory approvals pending
Equity dilution of existing shareholders from primary issuance
Execution and capital deployment risk for such a large cash pile
👀 கவனிக்க வேண்டியவை
Track the regulatory and shareholder approval timelines, customary closing milestones, and subsequent disclosures regarding preferential issue pricing, dilution details, and deployment plans for the Rs 3,150 crore infusion.
Yatharth Receives Total Tax Demands of ₹59.74 Cr (incl. Interest) Across Group; Filing Appeals
Yatharth Hospital and its subsidiaries (AKS Medical and Ramraja Multispeciality) have received final assessment orders concluding past income tax proceedings. Aggregate demands stand at Rs 29.66 Cr tax plus Rs 11.42 Cr interest for Yatharth, Rs 8.50 Cr tax plus Rs 2.48 Cr interest for AKS, and Rs 5.64 Cr tax plus Rs 2.04 Cr interest for Ramraja, totaling Rs 59.74 Cr. This total demand represents ~35% of FY26 TTM PAT (Rs 171 Cr). The company is appealing before the CIT (Appeals), expects substantial relief, and has made no financial provisions.
உச்சம் நம்பிக்கை
என்ன மாறியதுIncome tax assessment proceedings across opened assessment years have formally concluded with final demand orders issued against the parent and two subsidiaries.
ஏன் இது முக்கியம்The cumulative demand of Rs 59.74 Cr is substantial relative to annual profitability (~35% of TTM PAT), though the company has not provided for it pending appellate resolution.
📅 குறுகிய காலம்Litigation risk may create near-term overhang; key focus will be whether tax authorities demand a mandatory pre-deposit (typically up to 20%) during the appeal process.
📈 நீண்ட காலம்If demands are upheld, it would impact net cash reserves and require provisions against P&L, though core hospital operations and bed expansions remain unaffected.
⚠ அபாய எச்சரிக்கைகள்
Tax liability crystallisation risk if CIT (Appeals) dismisses petitions
Potential cash outflow if a pre-deposit is mandated to stay recovery proceedings
No financial provision created in current accounts
👀 கவனிக்க வேண்டியவை
Track the admission and hearing outcomes of the appeals filed before the CIT (Appeals), and check whether any stay on demand requires partial pre-deposits.
Q1 Revenue up 51% YoY to ₹392.7 Cr; EBITDA up 39% to ₹91.7 Cr with ARPOB at ₹34,758
Yatharth reported a 51% YoY revenue growth in Q1 to ₹392.7 Cr (INR 3,927 million) and a 39% YoY increase in EBITDA to ₹91.7 Cr, driven by mature units and rapid scaling of new hospitals. Newer hospitals contributed 27% to total revenue, with Faridabad Sector 20 achieving EBITDA breakeven within 9 months and Agra delivering 20%+ EBITDA margins. Group ARPOB rose 7% YoY to an all-time high of ₹34,758, with premium NCR facilities crossing the ₹50,000 mark. The company currently operates 2,555 beds and reiterated its roadmap to reach 5,000 beds over the next few years, alongside declaring a maiden 5% interim dividend.
உச்சம் நம்பிக்கை
என்ன மாறியதுYatharth published its Q1FY27 earnings call transcript highlighting record quarterly revenue, rapid acquisition turnaround, and plans for network expansion.
ஏன் இது முக்கியம்Demonstrates successful integration of acquired hospital assets, high ARPOB expansion via advanced specialties (oncology, robotics), and consistent operating leverage.
📅 குறுகிய காலம்Robust execution and improving profitability across acquired hospitals provide strong fundamental support.
📈 நீண்ட காலம்Doubling bed capacity to 5,000 beds and scaling high-margin oncology and robotics offerings provide strong multi-year compounding potential.
⚠ அபாய எச்சரிக்கைகள்
Geographic concentration in Delhi-NCR and North India
Execution and clinical talent retention risks associated with rapid bed additions
👀 கவனிக்க வேண்டியவை
Track the commercial launch timeline of the 250-bed Gurugram hospital scheduled for Q1 of the next fiscal, as well as occupancy gains in Noida Extension and brownfield expansions.
51% YoY Revenue Growth in Q1 FY27; Faridabad Unit Achieves EBITDA Breakeven
Yatharth Hospital reported a robust Q1 FY27 with revenue growing 51% YoY to ₹392.7 cr, significantly higher than the previous year's quarterly average. Operational efficiency improved as occupancy reached 68% (up from 65% YoY) and ARPOB increased 7% YoY to ₹34,758. Notably, the Faridabad Sector-20 unit achieved EBITDA breakeven within just 9 months, while the Agra unit delivered >20% margins in its first full quarter. The company also declared its first interim dividend of 5% of face value.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has successfully integrated recent acquisitions, with new units like Agra and Faridabad reaching profitability milestones faster than industry averages.
ஏன் இது முக்கியம்The rapid turnaround of new units validates the company's acquisition playbook and supports its high P/E valuation (49.2) by demonstrating scalable growth in the Delhi-NCR region.
Q1 FY27 Revenue: ₹392.7 கோடிRevenue vs TTM Revenue: 32.7%ARPOB: ₹34,758Adjusted EBITDA Margin: 28.1%Occupancy Rate: 68%Interim Dividend: 5% of Face Value
📅 குறுகிய காலம்The stock is likely to react positively to the strong top-line growth and the achievement of EBITDA breakeven in the Faridabad unit.
📈 நீண்ட காலம்The expansion to 2,800+ beds and entry into high-ARPOB segments like robotics and oncology provide a structural growth runway for the next 2-3 years.
⚠ அபாய எச்சரிக்கைகள்
Geographic concentration in North India
High attrition risk of specialized medical professionals
👀 கவனிக்க வேண்டியவை
Watch for the operational commencement of the Gurugram facility in Q1 FY2028 and the ability to maintain the 28% adjusted EBITDA margin as newer units mature.
₹0.50 Dividend Declared and 2.5 Lakh Share ESOP Scheme Approved by Yatharth Hospital
Yatharth Hospital reported a 34.9% YoY increase in standalone revenue for Q1 FY27, reaching ₹176.3 Cr compared to ₹130.7 Cr in the previous year. The Board declared a first interim dividend of ₹0.50 per share (5% of face value), with a total payout of ₹4.82 Cr. Additionally, a new ESOP Scheme 2026 was approved, covering 250,000 equity shares to incentivize and retain key employees. While revenue growth was robust, standalone PAT grew more modestly at 3.9% YoY to ₹28.17 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has reported its Q1 FY27 financial performance, initiated its first dividend for the fiscal year, and introduced a new employee stock option framework.
ஏன் இது முக்கியம்The strong revenue growth validates the company's expansion strategy in North India, while the ESOP scheme is a critical tool for retaining specialized medical professionals in a high-attrition industry.
Q1 Standalone Revenue: ₹176.3 கோடிYoY Revenue Growth: 34.9%Interim Dividend: ₹0.50 per shareDividend Payout vs TTM PAT: ~2.8%ESOP Shares: 2,50,000 யூனிட்கள்Standalone PAT: ₹28.17 கோடி
📅 குறுகிய காலம்The stock may see positive sentiment due to the dividend declaration and strong top-line growth, with immediate focus on the August 14 record date.
📈 நீண்ட காலம்The ESOP scheme supports long-term talent retention, which is vital for the company's goal of reaching 3,000 beds and increasing ARPOB through specialized treatments.
Potential equity dilution from the new ESOP scheme
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to translate high revenue growth into better bottom-line margins, as PAT growth lagged revenue this quarter. Watch for the upcoming record date of August 14, 2026, for dividend eligibility.
Rs 0.50 Interim Dividend: Yatharth Hospital Sets August 14, 2026, as Record Date
Yatharth Hospital has declared its first interim dividend for FY 2026-27 at Rs 0.50 per equity share (5% of face value). The Board of Directors fixed August 14, 2026, as the record date to determine shareholder eligibility. The total paid-up share capital involved is Rs 96.35 crore. Based on the current stock price of Rs 865.7, this specific payout represents a nominal yield of approximately 0.06%.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has officially scheduled the record date and confirmed the quantum for its first interim dividend of the 2026-27 financial year.
ஏன் இது முக்கியம்While the dividend amount is small relative to the share price, it signals a commitment to shareholder returns alongside the company's aggressive 30% growth strategy and geographic expansion.
Dividend per share: Rs 0.50Dividend as % of Face Value: 5%ரெக்கார்ட் தேதி: ஆகஸ்ட் 14, 2026TTM EPS: Rs 18.28Dividend Yield (approx): 0.06%
📅 குறுகிய காலம்The stock may see a minor price adjustment on the ex-dividend date (typically one business day before the record date) reflecting the Rs 0.50 payout.
📈 நீண்ட காலம்Limited structural significance; the company's long-term value is tied to its ability to scale ARPOB (currently Rs 25,080) and integrate new acquisitions in North India.
👀 கவனிக்க வேண்டியவை
Investors should note the record date of August 14 to ensure they hold shares in their demat accounts by this date to receive the payout. The focus should remain on the company's execution of its 3,000-bed capacity target rather than this minor dividend yield.
₹0.50 Interim Dividend and 34.8% YoY Revenue Growth for Yatharth Hospital in Q1 FY27
Yatharth Hospital has declared its first interim dividend of ₹0.50 per share (5% of face value) for FY27, amounting to a total payout of ₹4.82 Cr. The company reported standalone revenue of ₹176.31 Cr for Q1 FY27, representing a 34.8% growth compared to ₹130.72 Cr in the same quarter last year. Additionally, the board approved a new ESOP scheme for 250,000 shares to incentivize employees. The record date for the dividend is fixed for August 14, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has initiated its dividend cycle for FY27 and reported strong double-digit revenue growth for the first quarter.
ஏன் இது முக்கியம்The dividend payout, though small relative to PAT (~2.8%), signals management's confidence in cash flows, while the revenue growth validates the company's expansion strategy in the North India market.
Interim Dividend: ₹0.50 per shareTotal Dividend Payout: ₹4.82 கோடிDividend vs TTM PAT: ~2.8%Q1 Standalone Revenue Growth (YoY): 34.8%ESOP Shares: 2,50,000 யூனிட்கள்ரெக்கார்ட் தேதி: ஆகஸ்ட் 14, 2026
📅 குறுகிய காலம்The stock may see mild positive sentiment leading up to the record date of August 14, supported by the revenue growth figures.
📈 நீண்ட காலம்The company's ability to maintain high growth rates while expanding its bed capacity toward the 3,000-bed target remains the primary long-term value driver.
⚠ அபாய எச்சரிக்கைகள்
Geographic concentration in North India
Potential equity dilution from the new ESOP scheme
👀 கவனிக்க வேண்டியவை
Investors should monitor the sustainability of the 34% revenue growth and the impact of the new ESOP scheme on future earnings per share (EPS) dilution.
51% YoY Revenue Growth in Q1FY27; Yatharth Declares Maiden Interim Dividend
Yatharth Hospital reported a strong Q1FY27 with revenue surging 51% YoY to 392.7 cr, significantly outpacing its TTM growth trends. EBITDA grew 39% YoY to 91.7 cr, though margins compressed to 23.3% from 25.4% due to the ramp-up of new acquisitions. A key highlight is the Faridabad Sector-20 unit achieving EBITDA breakeven in just 9 months, while the board declared its first-ever interim dividend at 5% of face value. PAT growth was relatively muted at 8% YoY ( 45.4 cr) due to increased depreciation from recent capacity additions.
உச்சம் நம்பிக்கை
என்ன மாறியதுYatharth has successfully integrated recent acquisitions, with new units now contributing over a quarter of total revenue and one achieving breakeven ahead of schedule.
ஏன் இது முக்கியம்The results validate the company's acquisition-led growth strategy and its ability to quickly turn around new assets, supporting its long-term target of reaching ~3,250 beds.
Q1FY27 Revenue: 392.7 crRevenue vs TTM Revenue: 32.7%EBITDA லாப வரம்பு: 23.3%Adjusted EBITDA Margin: 28.1%New Hospital Revenue Share: 27%Interim Dividend: 5% of Face Value
📅 குறுகிய காலம்The stock is likely to react positively to the record revenue growth and the surprise maiden dividend, reflecting management's confidence in cash flows.
📈 நீண்ட காலம்The company is successfully scaling its hub-and-spoke model in North India; sustained ARPOB growth and bed additions provide a clear path for multi-year compounding.
⚠ அபாய எச்சரிக்கைகள்
Margin dilution during the initial ramp-up phase of new hospitals
High depreciation from aggressive capacity expansion impacting net profit growth
👀 கவனிக்க வேண்டியவை
Monitor the occupancy levels and margin improvement in the Agra and Faridabad units as they mature, and track the progress of the upcoming Gurugram hospital expansion.
Yatharth Hospital Completes ₹100 Crore Acquisition of Gurugram Hospital Asset
Yatharth Hospital has successfully finalized the acquisition of a hospital asset located in Sector 40, Gurugram, from RNY Healthcare Services Private Limited. The total consideration of ₹100 Crores has been fully paid, and the transaction formalities were completed on June 12, 2026. The asset is now registered under AKS Medical & Research Centre Private Limited, which is a wholly-owned subsidiary of the company. This acquisition marks a significant step in the company's expansion strategy within the National Capital Region (NCR).
முக்கிய அம்சங்கள்
Completed acquisition of hospital asset in Sector 40, Gurugram for ₹100 Crores.Asset registered under wholly-owned subsidiary AKS Medical & Research Centre Private Limited.Full payment of the ₹100 Crore consideration has been executed.Transaction follows the initial acquisition announcement made on May 13, 2026.
👀 கவனிக்க வேண்டியவை
Investors should monitor the integration of this new asset and its impact on bed capacity and revenue growth in the upcoming quarters. This expansion into the Gurugram market is a positive indicator of the company's scaling capabilities.
Yatharth Hospital Q4 FY26 Revenue Jumps 47% YoY to INR 3,416 Mn; FY26 PAT Up 30%
Yatharth Hospital reported a robust 36% YoY revenue growth for FY26, reaching INR 12,072 million, driven by strong performance in existing units and rapid ramp-up of new facilities. The company's EBITDA for the full year rose 30% to INR 2,921 million, while Q4 occupancy reached 71%. Strategic expansions include a new Gurugram facility and the integration of the Agra hospital, which is already generating INR 7 crore in monthly revenue. With a net cash position of INR 1,160 million, the company is well-positioned to reach its target of 5,000 beds within the next three years.
முக்கிய அம்சங்கள்
Consolidated FY26 revenue grew 36% YoY to INR 12,072 million with EBITDA margins at 24.2%.Q4 FY26 ARPOB improved to INR 33,282, with Noida Extension hitting a record INR 47.8k.New Delhi and Faridabad Sector 20 hospitals contributed 11% to Q4 revenue with superior payer mix.Acquired a Gurugram hospital project for INR 100 crore, expected to be operational by April 2027.Total bed capacity reached 3,200+ with a long-term target of 5,000 beds.
👀 கவனிக்க வேண்டியவை
Investors should view the strong ramp-up in new hospitals and the entry into the high-ARPOB Gurugram market as key growth catalysts. The company's ability to maintain a 98% cash conversion ratio provides significant financial flexibility for further brownfield expansions.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
